Table 3 Comparison between the patients receiving antifungal therapy and without antifungal therapy
|  | Antifungal therapy(n = 299) | No antifungal treatment(n = 94) | P value |
|---|---|---|---|
Age | 56.47 ± 19.19 | 61.13 ± 17.81 | 0.038 |
Male | 223(74.6) | 69(73.4) | 0.820 |
Underlying disease | |||
Solid tumor | 80(26.8) | 38(40.4) | 0.012 |
Hematologic malignancy | 39(13.0) | 9(9.6) | 0.370 |
Diabetes mellitus | 56(18.7) | 21(22.3) | 0.442 |
Chronic Cardiac disease | 88(29.4) | 36(38.3) | 0.107 |
Chronic Pulmonary disease | 44(14.7) | 8(8.5) | 0.121 |
Chronic renal failure | 29(9.7) | 13(13.8) | 0.258 |
Skin barrier compromised | 21(7.0) | 5(5.3) | 0.016 |
Prior surgical intervention (< 1 month) | 182(60.9) | 62(66.0) | 0.375 |
Corticosteroid use | 45(15.1) | 9(9.6) | 0.179 |
Prior antifungal agents use (< 6 month) | 76(25.4) | 12(12.8) | 0.010 |
Severity of clinical feature | |||
Fever (T > 38.2℃) | 244(81.6) | 65(69.1) | 0.010 |
Parenteral nutrition | 135(45.2) | 45(47.9) | 0.644 |
Mechanical ventilation | 113(37.8) | 34(36.2) | 0.777 |
Renal replacement therapy | 36(12.0) | 13(13.8) | 0.647 |
Central venous catheter | 242(80.9) | 74(78.7) | 0.637 |
Severe neutropenia | 36(12.0) | 6(6.4) | 0.338 |
APACHE II score | 11.86 ± 5.91 | 11.72 ± 5.37 | 0.928 |
SOFA score | 3.66 ± 3.56 | 4.22 ± 4.24 | 0.577 |